Skip to main content

Abbvie Inc(ABBV-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Why AbbVie Stock Flew Higher on Monday

Motley Fool - Mon Feb 5, 5:55PM CST

Still basking in the afterglow of an encouraging quarterly earnings report, AbbVie(NYSE: ABBV) stock saw a healthy 1.5% rise in price across Monday's trading session. What helped was a series of post-earnings price target increases from analysts tracking the healthcare company's fortunes.

AbbVie beat on both the top and bottom lines in its fourth quarter

AbbVie's Monday pop followed a nice rise on Friday, the morning it reported those results.

Although the company's fourth-quarter revenue fell by 5% year over year (to $11.1 billion), and its non-GAAP (adjusted) net income withered to just under $5 billion ($2.79) from the $6.4 billion in the same period of 2022, both headline figures topped the consensus analyst estimates.

Meanwhile, the healthcare company guided for an adjusted per-share net profit of $11.05 to $11.25 for the entirety of 2024. This was in line with the average prognosticator estimate of $11.24.

A clutch of price target raises

As often happens when a publicly traded company notches twin beats for a quarter, several analysts got more bullish on AbbVie's prospects Monday. One of the clutch of raisers was Piper Sandler's Christopher Raymond, who now feels the stock is worth $185 per share (he formerly valued it at $180).

Raymond maintained his overweight (buy) recommendation as he did so, commenting in a new research note that AbbVie stock is undervalued. He wrote that the company is "firing on all cylinders," particularly with respect to its immunology products.

Other analysts bumped their price targets higher, if only incrementally. One of the more cautious raisers was Bank of America Securities' Geoff Meacham, who added $2 to his level for a new tally of $167. Compared to his Piper Sandler peer, Meacham isn't as positive on AbbVie's prospects, as he kept his neutral recommendation on the shares intact.

Should you invest $1,000 in AbbVie right now?

Before you buy stock in AbbVie, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.

See the 10 stocks

*Stock Advisor returns as of February 5, 2024

Bank of America is an advertising partner of The Ascent, a Motley Fool company. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bank of America. The Motley Fool has a disclosure policy.

Paid Post: Content produced by Motley Fool. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe